5-Azacytidine, a DNA methyl transferase inhibitor, is effective in patients with myelodysplastic syndromes (MDS). Whether responses to 5-Azacytidine are achieved by demethylation of key genes or by cytotoxicity is unclear. Of 34 patients with MDS or acute myeloid leukaemia (AML) treated with 5-Azacytidine, 7 achieved complete remissions (CR) (21%) and 6 achieved haematological improvement. All six had less than 5% bone marrow (BM) blasts at the time of haematological improvements (HI) (2 had pre-existing refractory anaemia (RA), 4 had refractory anaemia with excess blasts (RAEB)). A further patient with RAEB had blast reduction to less than 5% without HI. Five of the seven (71%) complete responders had chromosome 7 abnormalities. BM CR predicted longer overall survival (OS) (median 23 versus 9 months, P ¼ 0.015). Bisulphite genomic sequencing (BGS) of the CDKN2B (p15
Introduction
The myelodysplastic syndromes (MDS) encompass a heterogeneous group of disorders characterized by bone marrow (BM) failure and an increased risk of myeloid leukaemic transformation. Non-random cytogenetic abnormalities occur in up to 50% of cases and are of prognostic importance. Isolated chromosome 7 abnormalities or complex cytogenetics confer adverse prognosis. 1 The median survival for patients with poor risk cytogenetics was 9 months in the original cohort studied by Greenberg et al.
2 that led to the IPSS scoring system. More recent studies show that despite improvements in supportive therapy, patients with chromosome 7 abnormalities have a median survival of only 15 months and a 36% risk of leukaemic transformation at 2 years. 3 Furthermore, these patients respond poorly to conventional acute myeloid leukaemia (AML)-type chemotherapy and have a high risk of relapse following allogeneic BM transplantation. 4 CDKN2B encodes p15 INK4b , a cyclin-dependent kinase inhibitor that is expressed selectively during myeloid and megakaryocytic but not erythroid differentiation. 5, 6 Transcriptional repression by aberrant hypermethylation of the CDKN2B promoter is frequent in MDS and is an independent prognosticator. [7] [8] [9] [10] CDKN2B promoter methylation has also been shown to correlate with the percentage of BM blasts and loss or deletion of chromosome 7, particularly in therapy-related MDS. 11 The potential reversibility of epigenetic gene silencing makes such genes an attractive target for therapy. Strategies aimed at achieving this include the use of DNA methyl transferase (DNMT) inhibitors 5-Azacytidine and its analogue 5-Aza 2 0 deoxycytidine, either as single agents or in combinations with histone deacetylase inhibitors. 5-Azacytidine is incorporated into both DNA and RNA in the cell, forms adducts with DNMTs and results in passive demethylation that potentially releases transcriptional inactivation of genes. 12 In the randomized Cancer and Leukemia Group B 9221 study, 5-Azacytidine induced haematological responses in 60% (complete remission 16%) in comparison with best supportive care. There was also a significant delay in leukaemic transformation (21 versus 13 months, P ¼ 0.007). 13 This and other studies have confirmed that several courses of 5-Azacytidine need to be administered in order to achieve a complete or partial response. As yet, specific clinical or biologic features that predict response to 5-Azacytidine have not been identified. Mechanistically it remains unclear whether the responses achieved were owing to demethylation of promoters of genes such as CDKN2B or cytotoxicity. We studied the methylation status of the CDKN2B promoter in patients with MDS, particularly those with high-risk cytogenetics, in order to determine whether its methylation status predicted responses to 5-Azacytidine and if demethylation correlated with the responses seen.
Materials and methods

Patients
Thirty-four patients with MDS (IPSS high, 15; Int-2, 13; Int-1, 5; and low, 1) were treated at King's College Hospital under the National Institutes of Health compassionate use protocol and the Pharmion-sponsored 5 AZA PH GL 003 trial with King's College Hospital local ethical board approval. Informed consent was obtained from all patients. Patients were required to have an ECOG performance status of 0-2, adequate cardiac performance (New York Heart Association less than II), serum creatinine and bilirubin o1.5x normal, liver enzymeso2 Â normal. The NIH protocol inclusion criteria were transfusiondependent MDS, previous therapy was permitted and patients with an allergy to mannitol were excluded. The other patients were untreated MDS patients with an IPSS score of 41.5 who had not had radiotherapy or chemotherapy and were not allergic to mannitol. A patient aged 16 years was treated on a protocol waiver for relapse after matched unrelated donor allograft.
Treatment 5-Azacytidine was administered subcutaneously at 75 mg/m 2 daily for 7 days and repeated every 28 days. The dosage was halved if the neutrophil count was o1 Â 10 9 /l 6 weeks from the start of the previous course. Of the 34 patients, 13 (38%) had dose reductions because of prolonged neutropenia. Patients who responded continued to be maintained on 5-Azacytidine therapy until relapse. Treatment was discontinued if there was clear evidence of disease progression. Response was assessed according to the International Working Group (IWG) criteria 1 after each course of treatment and reanalysed with the modified IWG criteria. 14 
Patient samples
BM aspirates and biopsies were obtained before the commencement of treatment and once in 4 months thereafter, or earlier if there was evidence of haematological response or disease progression. Pretreatment samples were available for 20 patients and paired samples before and after treatment were available in 17 patients. Owing to reports of early demethylation, BM was planned to be collected at day 7 of the first cycle of treatment in seven patients; however, three patients declined this, therefore four patients were sampled at this time point.
Analysis of promoter methylation Cell separation. Light-density cells were obtained by centrifugation of 5 ml BM aspirates for 30 min at 1800 r.p.m over Ficoll-Hypaque (Sigma, Gillingham, Dorset, UK). CD34 þ and CD33 þ cells were purified by immunomagnetic bead separation (Stem Cell Technologies, London, UK and Miltenyi Biotech, Surrey, UK). The purity of the CD34 þ cells was assessed by immunostaining and flow cytometry (BD Bioscience, Oxford, UK). Normal T cells were isolated from single-donor buffy coats by negative selection, as described previously. 15 Granulocyte colony stimulating factor (GCSF)-mobilized CD34 þ cells were isolated with immunomagnetic beads from apheresis products of peripheral blood.
DNA extraction and bisulphite treatment. DNA was extracted from the isolated cells using the abbreviated phenol/ chloroform method (Qiagen, Crawley, Sussex, UK). Following extraction, up to 1 mg DNA was modified with sodium bisulphite 16 19 An abnormal clone was defined if two cells had the same structural rearrangement or additional chromosomes or at least three cells with the same missing chromosome. The loss of chromosome 7 was confirmed by fluoresence in situ hybridization carried out by standard methods using a centromere-specific probe D7Z and a probe for band q31 of chromosome 7 (Cep7 probe, Vysis, Stuttgart, Germany). Cytogenetic responses to treatment were designated complete or partial as defined in the modified IWG criteria. 14 
Definition of response
The IWG and revised IWG criteria were used to assess response and treatment failure in responders. For non-responders, treatment failure was defined as the time when they progressed in their French-American-British stage or transformed to AML; or if they remained transfusion dependent before and during the study; or if they developed progressive BM failure (confirmed fall in all three cell lines of greater than 25% from baseline or greater than 50% in two cell lines or 475% in one cell line or if they became red blood cell transfusion dependent, not having required this previously). 13 
Statistics
Statistical evaluation was carried out using SPSS 14.0 statistical software. BM cellularity and methylation data were analysed using paired sample t-test; independent sample t-test was used for analysing patient disease characteristics. The Mann-Whitney U-test was used for analysing Annexin V/PI data. The overall survival (OS) was calculated as the time from commencing treatment to death or last follow-up. For patients achieving CR disease, free survival was defined as the time from commencing treatment to the time of relapse (DFS). The time to treatment failure was analysed from the time treatment commenced to the time of treatment failure. Survival and response duration were analysed by the Kaplan-Meier method and compared with the log-rank test. Table 1 .
Results
Study group and clinical response
CDKN2B methylation status and isolated chromosome 7 abnormalities K Raj et al
Ten patients had been pretreated: six with AML induction type chemotherapy; two with Tipifarnib, one with hydroxyurea; and one an allogeneic BM transplant. All patients were evaluable on an intention to treat basis. Three patients withdrew consent (two after one cycle, the third after two cycles following a diagnosis of bronchogenic carcinoma). Fourteen patients (41%) responded to treatment: seven had a complete remission (CR), six haematological improvements (HI) and one had blast reduction to less than 5% without HI.
Complete remission: Seven patients (20%) achieved CR after a median of two cycles; five had chromosome 7 abnormalities and two had trisomy 8.
Haematological Improvement: It occurred in 6/34 (18%) patients all of whom had less than 5% blasts at the time of HI (two RA and four RAEB that became RA). A further patient experienced reduction in blasts to less than 5% without HI. The median time to blast reduction less than 5% (BM CR in the revised IWG) was 64 days (mean 90.6745 days). HI-platelets occurred in six patients, HI-haemoglobin in two patients and HIneutrophils in three patients. In the pretreatment BM, there was no significant difference in blast % between those achieving BM CR and those with CR (P ¼ 0.26).
Cytogenetic responses: Twenty-seven patients had an abnormal karyotype before treatment. Complete cytogenetic remissions coincided with morphological CR in five patients. In two patients (del7 and a complex clone that included del5, del7 and del9), partial cytogenetic remission was observed at CR. One of these patients proceeded to complete cytogenetic remission after eight cycles of treatment, whereas the abnormal clone persisted until relapse with the other (data shown in Supplementary Table 2 ). A patient with trisomy 8 acquired a new clone after three cycles of treatment and this was accompanied by HI-P but no increase in blasts. Cytogenetic relapse with the same clone coincided with morphological relapse in two patients (À7/ del7) or followed cytopenic relapse in two patients (t8). A new clone at relapse was evident in a patient with del7 at relapse.
Adverse events
Localized injection site reaction (35%), nausea (32%), vomiting (20%), diarrhoea (14%) and constipation (38%) were the commonest non-haematological toxicity. Two patients were severely neutropenic throughout treatment and required GCSF administration. Grade 3 or 4 neutropenic sepsis (1 death) occurred in 17 patients (50%). Two (6%) patients experienced myalgia, renal impairment (grade 2) and hyperuricaemia after the first cycle of treatment.
Analysis of factors affecting response and survival
All 34 patients were analysed for factors affecting response and survival. The estimated median OS for all patients was 17 (95% CI 8.9-25) months. Reduction in BM blasts to less than 5% (n ¼ 12) led to a significantly improved OS of median 23 months. TTF for patients with isolated chromosome 7 abnormalities (n ¼ 5) was 20 (95% CI 10.6-29.4) months, whereas for all other patients (n ¼ 26) it was 4 (95% CI 2.6-5.4) months (P ¼ 0.07). The median TTF for patients achieving less than 5% blasts was 14 (95% CI 8.9-19.1) months as compared to those with 45% blasts (7 months, 95% CI 4.9-9.1) (P ¼ 0.9). There was no significant effect of age, sex, pretreatment haemoglobin, neutrophil or platelet counts, IPSS cytogenetic subgroups, IPSS score and blast percentage at presentation on response rates, and OS (Table 1) .
Promoter methylation before treatment and correlation with response
We studied the CDKN2B promoter, as it is frequently methylated in high-risk MDS and represents a target for epigenetic reactivation. Methylated CDKN2B was detected in 11
À cells (86%) and 5/5 CD3 þ , CD19 þ (100%) cells by methylation-specific PCR (MS-PCR). We sequenced five clones from five of these patients and showed that the methylated primers (biased to detect methylated alleles) only detected 100% hypermethylated alleles, that is alleles with all 12 CpGs methylated. In our hands, MS-PCR for CDKN2B is highly sensitive and detected one hypermethylated allele in 1000 (data not shown), a sensitivity similar to that reported previously. 20 Because of this sensitivity, we could not exclude the fact that we were detecting hypermethylated alleles in minor sub-populations of cells. We therefore analysed CDKN2B promoter methylation by bisulphite genomic sequencing (BGS) in CD34 þ , CD33 þ and CD3 þ , CD19 þ lineages at presentation and at CR/BM CR or non-response. BGS was also routinely carried out on samples of the Raji cell line and normal neutrophils, T (CD3 þ ) lymphocytes and CD34 þ progenitor cells as controls. The primers detected 100% methylated alleles and also detected the correct proportion of methylated alleles in a 50:50 and 80:20 mix of Raji and normal neutrophil DNA (not shown). The mean methylation in normal T lymphocytes and CD34 þ cells was 2.74% (n ¼ 6) and 2.17% (n ¼ 11), respectively. Lymphocytes from MDS patients were included in our analyses as previous data suggested that CDKN2B was methylated in lymphocytes of AML patient. 9 However, methylated alleles, with 430% methylation, were detected in seven patients, four of whom were treated with 5-Azacytidine. BGS of patient samples identified three patterns of promoter methylation (Figure 1 ). Pattern 1 occurred in 13 patients in whom all cell lineages showed sparse methylation. Pattern 2 was present in one patient in whom methylation of CD3 þ and CD19 þ lymphoid cells dominated, with occasional methylation of the CD33 þ myeloid cells. Pattern 3 occurred in three patients in whom CD33
þ , CD34 þ , CD3 þ and CD19 þ cells, all showed hypermethylated clones. Selected samples were validated by bisulphite pyrosequencing and showed similar methylation results ( Table 2) .
The most methylated cell type or mononuclear cells from these patients were analysed for differences in methylation by BGS before and after treatment with 5-Azacytidine. Pretreatment (n ¼ 17) methylation of the 45 CpGs across the promoter ranged from 3 to 34% with a mean methylation of 12.2% (s.e. 2.2%). Methylation following treatment with 5-Azacytidine at CR or non-response was mean 13.3% (s.e. 2.4%). Although eight patients had decreased methylation following treatment with 5-Azacytidine (mean reduction 6.2% (s.e. 2.2%), the difference in methylation between paired samples was not significant (paired t test P ¼ 0.77). Because 5-Azacytidine may mediate demethylation early, we examined the methylation status of CDKN2B at day 7 of the first cycle of treatment. There was no significant difference in methylation status at this time point (n ¼ 4; P ¼ 0.8) and there was no decrease in methylation. Samples were also analysed by bisulphite pyrosequencing, which correlated with the BGS data. An example is shown in Supplementary Figure S1 . The mean methylation state of patients who responded to treatment was 9.7% (s.e. 2.2%) compared with 16.7% (s.e. 4.2%) in non-responders (student's t-test P ¼ 0.07). Six patients (three responders; three nonresponders) increased methylation after treatment compared with baseline. In three of these patients, a clonal pattern was evident with three regions (CpG1-4, 21-26 and CpG 38) preferentially methylated ( Figure 2 ). The increase in methylation at CpG 1-4 was also confirmed by pyrosequencing (Supplementary Figure S1 , patient 2).
In order to determine whether the CDKN2B gene was transcribed in individual patients, the expression of mRNA encoded by CDKN2B was detected by reverse transcription-PCR (RT-PCR). The mRNA was detected in 11/14 patients for whom RNA was available. mRNA (Supplementary Figure 2) was not detected in three patients with X24% methylation. These three patients did not respond to treatment (t-test P ¼ 0.003) and had mean methylation (pyrosequencing) of 24, 25 and 34% respectively.
Bone marrow cellularity and apoptosis
BM cellularity, assessed histologically from BM trephines, reduced significantly from 80 (10-90%) to 30% (10-90%) following a median of six cycles (2-14 cycles) of 5-Azacytidine (P ¼ 0.001). The cellularity in responders was mean 62.3% (median 50% pretreatment), whereas that in non-responders was mean 67.5% (median 85% pretreatment) and was not significantly different (two sample t-test with unequal variance P ¼ 0.5). In responders (n ¼ 13), the cellularity reduced from median 50 to 30% (paired t-test P ¼ 0.01). In contrast, the reduction in cellularity in non-responders (n ¼ 8) was from median 85 to 65% (P ¼ 0.223). In five patients, cellularity reduced to less than 20% and was associated with prolonged neutropenia requiring alteration in dosing schedule. Early BM hypocellularity (10% cellularity) occurred in three patients following two and four (two patients) cycles of treatment respectively. This was accompanied by increasing platelet and blood transfusion dependence without an increase in blasts. Late BM hypocellularity (after 10 or more cycles of treatment) occurred in three patients.
As there was little evidence for demethylation of CDKN2B in patients treated with 5-Azacytidine and there was evidence of decreasing BM cellularity post treatment, we studied whether this was reflected by increased apoptosis. PI/Annexin V staining of the BM mononuclear cells was carried out before and at response (BM CR) or non-response following treatment with 5-Azacytidine. Pretreatment Annexin V/PI positivity (n ¼ 15) was mean 9.35% (95% CI 0.59-24.9%; s.e.m. 2.09%). Post-treatment Annexin V staining (n ¼ 17) was mean 15.35% (95% CI 1.65-80%; s.e.m. 4.63%). The mean Annexin V for non-responders (n ¼ 5) was 5.98% (s.e.m. 2.788%), which was CDKN2B methylation status and isolated chromosome 7 abnormalities K Raj et al CDKN2B methylation status and isolated chromosome 7 abnormalities K Raj et al significantly different from that of responders (n ¼ 12), 19.26% (s.e.m. 6.1%) (P ¼ 0.027).
Discussion
In this study, we show that sustained responses to 5-Azacytidine occur in patients with del/-7, and that the baseline CDKN2B promoter methylation rather than demethylation may differentiate responders from non-responders. Increased apoptosis and reduced BM cellularity also correlated with clinical response.
In our cohort of 34 patients, 12 patients achieved BM CR or CR. Within the IPSS high-risk group (15 patients), all patients with isolated chromosome 7 abnormalities (n ¼ 5, median IPSS 43, median age 67 years) had a response to 5-Azacytidine (median disease-free survival 20 months). Only 1/10 patient with complex cytogenetics attained CR (10 months). Lubbert et al. 21 showed that 38% of patients with high-risk cytogenetics treated with Decitabine (4120 mg/m 2 per cycle) achieved major cytogenetic responses (median survival 13 months). Of these, 4/6 patients with a del7/-7 achieved major cytogenetic response after two cycles of Decitabine (median duration 13 months). Kantarijan et al. 22 showed that in patients treated with 135 mg/m 2 Decitabine, 4/26 (all with del7) patients with highrisk cytogenetics responded with CR. Interestingly, the same group reported that del7/-7 with or without additional cytogenetic abnormalities was an independent adverse prognostic factor for survival (IPSS41.0, CR obtained in 5/18, median survival 7 months), whereas patients with complex cytogenetics experienced CR in 8/10 patients (median survival 26 months) when treated with 100 mg/m 2 Decitabine per course. These differential responses to Decitabine and Azacytidine in the highrisk cytogenetic group may be dose-dependent or owing to variations in the way both drugs work at the doses used. Our findings in patients with del/-7 need to be confirmed in larger studies.
HI occurred only in patients who had less than 5% blasts (n ¼ 6). Of these, four were patients with RAEB, and an additional patient with RAEB, who also achieved less than 5% blasts but did not experience HI, would meet the criteria for BM CR as proposed in the revised IWG criteria.
14 This was associated with a longer OS (median 23 months in comparison with 9 months). It preceded HI suggesting that BM blast clearance is necessary for HI.
Baseline CDKN2B methylation studied by MS PCR (sensitivity 1 Â 10 À4 ) confirms the presence of a hypermethylated allele in 68 (CD34 þ cells) to 100% (CD3 þ /CD19 þ ) of our patients based on cell type. However, using the more quantitative methods, BGS and bisulphite pyrosequencing, we found lowlevel overall methylation of the CDKN2B promoter, which was non-clonal and variegated in most patients, whereas hypermethylation was observed in only a few patients. Previous studies of CDKN2B methylation by double gradient gel electrophoresis 9 and BGS 23 also found a lower incidence of methylation in comparison with that detected by MS-PCR. Hypermethylation of the CDKN2B promoter was reported using BGS in patients with chronic myelomonocytic leukaemia (CMML). 24 In the patient with CMML studied here, 32% methylation in the CD33 þ fraction was noted. The difference in sensitivities of these techniques suggests that the hypermethylation of CDKN2B detected by MS-PCR in the majority of patients represents only a small proportion of alleles. Identification of the cellular sub-population in which this occurs is important as hypermethylation of the CDKN2B promoter by MS-PCR has consistently been shown to be an adverse prognostic factor in MDS.
Interestingly, hypermethylated alleles were detected most often in the lymphocyte fraction (lymphocytes alone, four patients; all cell types, three patients). MDS (conventionally a myeloid disease) is associated with immune phenomena 25, 26 and clonal cytotoxic T lymphocytes occur in 97% of MDS patients. 27 The CDKN2B hypermethylated alleles in the lymphocytes may represent such pathogenic oligoclones or subpopulations. Whether this methylation is due to a defect in the lymphoid lineage or is a response to the underlying myeloid abnormalities needs further investigation.
We studied the correlation between the degree of CDKN2B methylation across 45 CpG sites before treatment (median 9.6%, mean 12.2%, range 1.3-34%, nine patients had 410%) and at response. The mean methylation in responders was 9.7%, whereas it was 16.8% in non-responders. Patients with 424% methylation, not expressing p15 INK4b , did not respond. Reduction in CDKN2B methylation (mean 6.2%) was observed, but it did not correlate with response. Yang et al. 28 showed similar low-level methylation of the CDKN2B promoter at baseline by bisulphite pyrosequencing (median 4%, mean 12.1%, range 0-73.8%, 10/37 had 410% methylation). Similarly, their study showed that methylation decreased by mean 5.1% and did not correlate with response to Decitabine. Mean methylation in responders was at a low level (5%), whereas it was higher in non-responders (15.9%). No response was observed in patients with 425% methylation but the expression of p15
INK4b was not studied. Kantarijan et al. 29 also reported CDKN2B methylation in 14% of MDS and CMML patients by bisulphite pyrosequencing, but did not find any difference in the distribution of hypermethylated CDKN2B between responders and nonresponders (incidence of 15% in both at baseline). Thus 85% of those achieving CR did not have hypermethylated CDKN2B, implying that its demethylation was not necessary for response.
Expression of p15
INK4b studied at baseline and day 5 also did not differentiate responders/non-responders, but those achieving CR had significant increase in p15
INK4b at day 12 and at peripheral blood recovery. In our cohort, expression of p15
INK4b mRNA (RT-PCR) was detected in all but three patients, consistent with the finding of low-level methylation in the CDKN2B promoter. The absence of mRNA in samples with greater than 24% methylation suggests that this may approximate the critical level of methylation for silencing this gene. Garcia Manero et al. 30 also proposed that the pretreatment CDKN2B methylation (pyrosequencing) status correlates, with responses to a combination of Decitabine and Valproate with low levels of methylation (mean 11.4% versus 22.3%) predicting response.
In contrast, Daskalakis et al. 31 reported late demethylation (3.5 cycles) of the CDKN2B promoter (methylation-sensitive primer extension assay) in 9/12 patients with 410% methylation, and this correlated with response to Decitabine. However, two patients who were not hypermethylated also responded. Gore et al. 32 also demonstrated that 5-Azacytidine (cumulative dose 500-700 mg/m 2 ) induced early demethylation (first cycle, days [10] [11] [12] [13] [14] at the CDKN2B promoter in 3/5 hypermethylated patients (BGS and MS-PCR), which correlated with response.
In the present cohort, four patients were studied for early changes in methylation by BGS, 7 days post treatment. Reduced methylation from 9.6 to 3.3% was observed in a responder, and the other three patients with methylation (424%) did not demethylate or respond. We also observed demethylation by MS-PCR in two patients who were largely unmethylated by BGS (patients 1 BM CR and 4 CR), suggesting that this was due to loss of a minor hypermethylated clone. This could represent demethylation of a small group of effector cells such as lymphocytes, as suggested above.
Thus we confirm that there is intra-and inter-individual heterogeneity in CDKN2B methylation in MDS 9 and furthermore suggest that this heterogeneity at baseline may predict responses to 5-Azacytidine. The experience in MDS with Decitabine has shown similarly that less than 10-11% methylation at CDKN2B correlates with response; [28] [29] [30] when methylation exceeds 10%, demethylation correlates with response, 31, 32 but with high levels of methylation (424-25%), this occurs less frequently and patients do not respond. 28 In addition to its effects on DNA methylation, 5-Azacytidine induces apoptosis. 33 Annexin V/PI data on the patients in our study indicate that BM mononuclear cell apoptosis is low before treatment as expected in high-risk MDS 34 and increases following treatment with 5-Azacytidine. This persists in some patients even after achieving CR and may account for the BM hypocellularity evident in some of the patients. Increased apoptosis may effect CR or may be due to the change in the differential population of BM cells in CR. There are no comparative in vivo studies of apoptosis with either 5-Azacytidine or Decitabine.
The sustained response in patients with del/-7 treated with 5-Azacytidine needs confirmation in a larger cohort. At 75 mg/m 2 x7d of 5-Azacytidine, patients who have less than 10% methylation at CDKN2B appear to respond, indicating that demethylation of CDKN2B is perhaps not the predominant mechanism at this dose. Increased apoptosis suggests that demethylation of other genes or cytotoxicity may play a role in mediating the effects of 5-Azacytidine. The poor responses in patients with 424% methylation suggests the need for tailored therapy (alternative doses/combination strategies) to optimize their responses.
